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Background: The rise of antimicrobial drug resistance in Mycobacterium tuberculosis coupled with the shortage
of new antibiotics has elevated TB to a major global health priority. Repurposing drugs developed or used for
other conditions has gained special attention in the current scenario of accelerated drug development for several
global infectious diseases. In a similar effort, previous studies revealed that carprofen, a non-steroidal anti-in-
flammatory drug, selectively inhibited the growth of replicating, non-replicating and MDR clinical isolates of
M. tuberculosis.
Objectives: We aimed to reveal the whole-cell phenotypic and transcriptomic effects of carprofen in
mycobacteria.
Methods: Integrative molecular and microbiological approaches such as resazurin microtitre plate assay, high-
throughput spot-culture growth inhibition assay, whole-cell efflux inhibition, biofilm inhibition and microarray
analyses were performed. Analogues of carprofen were also synthesized and assessed for their antimycobacte-
rial activity.
Results: Carprofen was found to be a bactericidal drug that inhibited mycobacterial drug efflux mechanisms.
It also restricted mycobacterial biofilm growth. Transcriptome profiling revealed that carprofen likely acts by tar-
geting respiration through the disruption of membrane potential. The pleiotropic nature of carprofen’s anti-TB
action may explain why spontaneous drug-resistant mutants could not be isolated in practice.
Conclusions: This immunomodulatory drug and its chemical analogues have the potential to reverse TB anti-
microbial drug resistance, offering a swift path to clinical trials of novel TB drug combinations.
Introduction
In 2018, 10 million people developed active TB and an estimated
1.5 million died from the disease.1 Since the introduction of the
multidrug therapeutic regimen for drug-susceptible (DS)-TB, re-
search priorities have focused elsewhere, resulting in only three
new anti-TB drugs being released over the last 40 years. Some
Mycobacterium tuberculosis strains, in the meanwhile, have
acquired genetic mutations that render them resistant to most
antibiotics.2 As the number of effective antibiotics falls, drugs that
can be rolled out immediately have fuelled interest in drug
repurposing, the process of identifying commercially approved
drugs used for other indications or diseases that also exhibit anti-
mycobacterial properties.3–7 This approach benefits from prior
knowledge of the drug’s safety and metabolic properties, as these
are already approved by the FDA and EMA for use in humans.
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used for pain relief. The common NSAIDs aspirin and ibuprofen
have been reported to decrease the size and number of lung
lesions and the bacillary load and to improve survival rates in
murine models of TB.8,9 Ibuprofen and diclofenac enhance the
activity of pyrazinamide and streptomycin, respectively, when
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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administered in the initial phase of TB treatment in mice.10,11
Antimycobacterial activity of oxyphenbutazone has been reported
against replicating, non-replicating and drug-resistant forms of
the pathogen while also working synergistically with several anti-
TB drugs. An in vitro infection model indicated that diflunisal and
bromfenac possess antimycobacterial properties.12 Conversely, a
study demonstrated that ibuprofen and celecoxib increase bacter-
ial loads in mice infected via aerosol challenge as opposed to the
IV infection route adopted in the investigations discussed above.13
Another study (NCT02602509) using a whole-blood bactericidal
activity model demonstrated that celecoxib did not potentiate
rifampicin or pyrazinamide.14 This highlights the importance of
developing and testing on appropriate animal/ex vivo models, as
well as the gap in knowledge concerning at which stage of infec-
tion (early or late) NSAIDs should be administered for maximal
benefit.
A limited number of clinical studies are currently exploring the
potential of NSAIDs in TB control. NCT02060006 is a Phase 3 trial
to identify whether meloxicam can prevent TB immune reconstitu-
tion inflammatory syndrome, a serious clinical issue in HIV-
coinfected TB patients. Other trials include a pilot (Phase 2) clinical
study (NCT02237365) of aspirin as an adjunctive treatment for TB
meningitis and a trial (Phase 2) of ibuprofen for the treatment of
XDR-TB in addition to the standard therapy (NCT02781909). The
immunomodulatory function of NSAIDs (etoricoxib) in increasing
the protection offered when administered alongside a TB vaccine
is being investigated in the trial NCT02503839.
A previous drug-screening study from our group revealed car-
profen, an NSAID, to selectively inhibit the growth of replicating,
non-replicating and MDR clinical isolates of M. tuberculosis at
40 mg/L.15
Though the general antibacterial activity of NSAIDs has been
reported independently for a few years,4,16 the mechanisms by
which they exert their antibiotic action on M. tuberculosis are not
understood.
In this study, we reveal carprofen’s potential to reverse anti-
microbial resistance in TB through its pleiotropic modes of action.
This, in addition to its role as an immunomodulator in the host,
offers great potential in anti-TB therapy.
Methods
All chemical reagents were sourced from Merck (previously Sigma–Aldrich)
unless otherwise mentioned.
Experimental models and subject details
M. tuberculosis H37Rv (ATCC 25618) and Mycobacterium smegmatis
mc2155 (ATTC 700084) cultures were maintained at 37C as standing cul-
tures or with 150 rpm shaking, respectively, using Difco Middlebrook
(M)7H10 agar/7H9 broth (BD Biosciences/Merck) supplemented with 0.2%
(v/v) glycerol, 0.05% (v/v) Tween 80 (broth only) and 10% (v/v) Middlebrook
OADC growth supplement (BD Biosciences/Merck) or Middlebrook ADC,
respectively. All bacterial cultures were passaged at least twice from
cryogenically preserved stocks before use in experiments.
Resazurin microtitre plate assay (REMA)
Mid-log phase (OD6001.0–1.20) M. smegmatis was diluted (10#3) in M7H9
and 100lL of inoculum was tested against a concentration range of car-
profen. The plates were incubated at 37C for 24 h, then 30lL of resazurin
solution (5 mL of resazurin reagent mixed with 5 mL of 20% Tween 80)
was added to each well and incubated at 37C for 6–9 h. The MIC was
determined as the minimum drug concentration where the colour of the
suspension in the microtitre plate well remained blue.
Inhibition of multidrug efflux pumps in a whole-cell
setting
Accumulation assay
Early-log phase bacteria (OD600  0.8) were adjusted to OD600 = 0.4 and
resuspended in 1% PBS. Each reaction contained 4–6%107 cfu/mL in PBS for
M. smegmatis, 0.4% glucose, 0.5 mg/L ethidium bromide (EtBr) and subMIC
concentrations of the antimicrobial drugs being tested. Negative controls
contained all components but with the bacterial suspension replaced
with 1% PBS. The experiment was performed in 96-well plates that were
placed in a fluorimeter (BioTek Synergy 2) programmed with the following
parameters: wavelengths of 544 nm and 590 nm for excitation and detec-
tion of fluorescence, an incubation temperature of 37C and a cycle of
measurement every minute for a total period of 60 min.
Efflux assay
The cells were prepared as above and packed with EtBr by incubating with
1 mg/L EtBr and verapamil at 25C for 1 h. Following incubation, cells were
centrifuged at 4C and the supernatant removed before addition of cold 1%
PBS to the bacterial pellet to obtain a bacterial suspension. EtBr efflux
was measured in a 96-well plate in 100lL volumes containing subMIC
concentrations of the compounds, 0.4% glucose and 4–6%107 cfu/mL.
Fluorescence was read using the parameters described above. All experi-
ments were performed in triplicate.
Growth and maintenance of mycobacterial biofilm
For cultivation of biofilms, M. smegmatis was grown to late-log phase
(OD600 > 6.0), harvested and resuspended (1:100 dilution) in Sauton’s me-
dium. The bacterial suspension was incubated at 37C for 5 days without
shaking.
cfu counting and OD determination of biofilms
Biofilms were grown in polypropylene (PPE) tubes then vortexed to result in
a uniform cell suspension. One millilitre of the suspension was used to read
the OD600 corrected against a blank containing sterile medium. One hun-
dred microlitres of the bacterial suspension was diluted (dilution series
10#3 to 10#8 of the original) and 100lL of each dilution was spread on
M7H10 plates. The plates were incubated for 3 days at 37C before counting
and SD was calculated.
Confocal laser scanning microscopy
M. smegmatis biofilms were grown in 6-well plates (Corning), pre-loaded
with sterilized glass coverslips. Sauton’s medium containing 0.25% MIC of
carprofen was used for the experiments. Drug-free and solvent controls
were also set up. Coverslips were removed, making sure they lifted the bio-
film, and 20lL of 6lM propidium iodide (PI) and 20lL of 4lM Nile red were
added onto each coverslip placed on a slide separately as the excitation
and emission wavelengths for these dyes overlap. Each dye was added
45 min prior to visualizing with confocal laser scanning microscopy (Leica,
SP5) to allow the dye to penetrate. Biofilms were analysed though a series
of images in the z-axis, followed by selection of optical planes.
Maitra et al.
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Crystal violet staining of biofilms
Once biofilms were formed in 96-well plates, the medium containing plank-
tonic cells was aspirated and the plate was dried. Crystal violet (0.1% w/v)
was added to the biofilms and left for 30 min at room temperature.
The stain was removed and 30% acetic acid was added to solubilize the bio-
film. Absorbance was measured at OD600 using a plate reader (BioTek
Synergy 2). All experiments were performed in three independent biological
replicates.
Quantification of extra-polymeric substance (EPS)
Biofilms were grown in PPE tubes in the presence of a dilution series of car-
profen (2–0.25%MIC; 500–62.5 mg/L). Solvent and drug-free controls were
also set up. The biofilm was disrupted by gentle vortexing and moved to
15 mL centrifuge tubes, followed by centrifugation at 3000g for 1 h at
25C. The supernatant and pellet were moved into separate microfuge
tubes and filtered through 0.22lm filters to remove whole cells and debris.
Each fraction was analysed for protein and carbohydrate content using the
Bradford Assay and the Phenol Sulphuric Acid Assay,17 respectively.
Twenty-five microlitres of each fraction was added to a 96-well round-
bottom black plate (Corning) followed by 15lL of 4lM Nile red and
incubated for 15 min prior to reading at 488–530 nm (excitation) and
575–580 nm (emission) to estimate lipid content. All experiments were
performed in three independent biological replicates.
RNA extraction
Mid-log phase cultures of M. tuberculosis (10 mL) were treated with 10%
MIC carprofen (400 mg/L), ibuprofen (750 mg/L), ketoprofen (750 mg/L)
or isoniazid (5 mg/L) for 4 h. The cultures were harvested by addition of 4
volumes of GTC solution (5 M guanidine thiocyanate, 0.1 M Tris-HCl, pH 7.5,
and 0.1 M b-mercaptoethanol). Total RNA was extracted using the
FastRNAV
R
Blue Kit (MP Biomedicals), following the manufacturer’s
instructions.18,19
The RNA was then further purified using the RNeasy kit (QIAGEN),
following the manufacturer’s instructions. To remove genomic DNA
contamination, the RNA samples were treated with the Turbo DNA-free
Kit (Ambion), according to the manufacturer’s instructions. Spectrophotom-
etry was performed (NanoDrop 2000 machine, Thermo Scientific) to
quantify the RNA concentration.
Microarray analysis
Mycobacterial RNA (2lg) was directly labelled with Cy3 fluorophore using
the Universal Linkage System (ULS, Kreatech Diagnostics). Microarray
hybridizations from three biological replicates were conducted, as previous-
ly described,20,21 using an M. tuberculosis microarray (Agilent Technologies)
designed by the Bacterial Microarray Group at St. George’s (ArrayExpress ac-
cession number ABUGS-41). Significantly differentially expressed genes
were identified comparing drug-treated to carrier control (DMSO-treated)
using a moderated t-test (P value <0.05 with Benjamini and Hochberg mul-
tiple testing correction) and a >3.5-fold change. Significant overlaps in tran-
scriptional signatures were identified using hypergeometric probability.
Fully annotated microarray data have been deposited in Array Express (ac-
cession number E-MTAB-6191).
Membrane potential assay
The membrane potential assay was performed using the BacLightTM
Bacterial Membrane Potential Kit (Thermo Fisher Scientific) with slight mod-
ifications. M. smegmatis culture (OD600 = 1) was resuspended in PBS. Two
hundred microlitres of the cell suspension was added to the wells of a black,
flat-bottom 96-well plate. To each well, 2lL of the DioC2(3) (provided in the
kit) and 2lL of drug (or DMSO) were added. For isoniazid, 1=4% MIC was
used, whereas for carprofen and CCCP, various concentrations were tested.
The plate was incubated in the dark at 37C for 30 min. It was read in a
plate reader (BioTek Synergy 2), with excitation at 485 nm and emission
readings taken at 540 nm and 620 nm. The ratio of red/green fluorescence
was calculated for each well and the values were normalized. All experi-
ments were performed at least in triplicate (n = 3), with the drug-free and
isoniazid controls performed using n = 6.
High-throughput spot-culture growth inhibition assay
(HT-SPOTi)
HT-SPOTi was used to assess the MIC of carprofen and 2-(6-chloro-9H-car-
bazol-3-yl)acetic acid against M. smegmatis as described in our earlier pub-
lications.15,22,23 The plates were incubated at 37C for 2 days. The MIC was
determined as the lowest concentration of the compound where visible
mycobacterial growth was not observed.
Results and discussion
Carprofen inhibits efflux pump activity in mycobacteria
REMA assays determined the MIC of carprofen for M. smegmatis to
be 250 mg/L. EtBr (a known substrate for bacterial efflux pumps)
accumulation and efflux assays performed on M. smegmatis
exposed to a subinhibitory concentration of carprofen (62.5 mg/L,
0.25%MIC), showed carprofen to inhibit efflux pumps to the same
extent as the potent efflux pump inhibitor verapamil (Figure 1a
and b).
Inhibition of drug efflux as part of a combination therapy can
alter the efficacy of the treatment in three ways: (a) potentiate
treatment (increase effectiveness at lower doses) in drug-
susceptible bacilli; (b) reverse resistance (partially or completely) in
some genetically resistant bacilli; and (c) shorten the duration of
treatment by targeting ‘persister’ or ‘drug-tolerant’ phenotypes.
These routes of tackling antimicrobial resistance offer great prom-
ise.24,25 Verapamil is a Ca2! channel blocker used to treat cardio-
vascular disorders and has been shown to restore the susceptibility
of MDR-TB strains to rifampicin, isoniazid and bedaquiline, among
others.26 A similar investigation on carprofen is required. Whether
carprofen inhibits efflux via direct binding to the pumps or through
indirect mechanisms such as ATP sequestration or disturbing the
membrane potential, or a combination of these strategies, is still
to be determined. An additional gap in our understanding is
whether carprofen can serve as a substrate for the pumps.
In bacteria, verapamil is believed to target the ATP-dependent
multidrug transporters and MDR pumps by blocking the generation
of the proton motive force26 and this could be a likely mechanism
of action for carprofen. One of the molecular targets of carprofen
in humans is cyclooxygenase-2 (COX-2), an enzyme that has been
under investigation for its role in regulating efflux mechanisms via
MDR1 proteins and development of a drug-resistant phenotype in
cancerous tissue.27 Celecoxib is a COX-2 selective inhibitor that has
been shown to reverse the drug resistance of cancers and bacteria
alike.28,29 We expect both drugs to share some commonalities in
their mechanism of action; however, unlike celecoxib, carprofen
directly kills mycobacteria.
Carprofen affects mycobacterial biofilm phenotype
Bacterial efflux pumps are implicated in quorum sensing (QS),
which plays a crucial role in the regulatory processes of
Repurposing non-steroidal anti-inflammatory drugs JAC
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Figure 1. Whole-cell phenotypic effects of carprofen treatment on M. smegmatis. (a) Inhibition of efflux pumps in the presence of subMIC concentra-
tion of carprofen (CRP) (0.25% MIC, 62.5 mg/L) as seen through the accumulation of EtBr and resulting increase in the fluorescence readout.
Verapamil (VP) (0.25% MIC, 50 mg/L) was used as positive efflux pump inhibitor control. Untreated cells served as the negative control. The experi-
ments were performed in triplicate (n = 3) and the graph was plotted using the averages. (b) Efflux of EtBr from pre-saturated cells in the presence of
carprofen and verapamil, showing retention of the efflux pump substrate. (c) Complete inhibition of biofilm formation is observed in the presence of
250 mg/L (1% MIC) of carprofen in the PPE tubes and 96-well plates within a timescale of 5 days. Confocal images of stained extracellular DNA and
lipids show distinct differences between carprofen-treated and untreated biofilms, especially their wrinkled surface, as captured in the z-axis images.
(d) Concentration-dependent effect of carprofen on biofilm formation, as quantitated by crystal violet staining of the biofilms. Panels e, f and g show
the amount of EPS, namely lipids, proteins and carbohydrates that make up the biofilms of the untreated control and carprofen-treated biofilms
(0.25%MIC).
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attachment and dispersion of biofilms30,31 mediated via small
intracellular signalling molecules. Salicylic acid and propionic acid
moieties and their derivatives are common structural features in
NSAIDs that have been previously reported to inhibit biofilm for-
mation or to disrupt the mature biofilms of many bacterial and
fungal species such as Candida spp.32 Therefore, we developed a
mycobacterial biofilm model to test the effect of carprofen on bio-
film formation. At its effective MIC against planktonic M. smegma-
tis cells (250 mg/L), carprofen inhibited biofilm formation
(Figure 1c), as was also noted by OD measurements (Figure 1d).
Treatment with 0.25% MIC carprofen did not have any significant
reduction on the viability of the biofilm (Figure S1, available as
Supplementary data at JAC Online). Therefore, 0.25% MIC was
used to measure the effect of carprofen on the EPS of mycobacter-
ial biofilms. At this concentration, carprofen affected the levels of
carbohydrates, but not proteins or lipids, of the mycobacterial bio-
films (Figure 1e, f and g). These results need further investigation in
the light of the transcriptomic signature of carprofen exposure as
described below. Further experiments to understand whether car-
profen can break down previously formed biofilms and the effect
of drug exposure on the carbohydrate metabolites within the cell
need to be performed.
Confocal microscopy using PI and Nile red, dyes that specifically
stain extracellular DNA and lipids, respectively, was used to deter-
mine whether carprofen affected these key biofilm constituents.
Carprofen exposure resulted in distinctive changes to the patterns
of aggregation of these macromolecules in mycobacterial biofilms
(Figure 1c). Extracellular DNA is known to play a role in the architec-
tural composition of biofilms and any modification in its release
and aggregation may explain the phenotype observed in
treated biofilms (Figure 1c). The z-axis cross-section of the biofilms
reveals that carprofen-treated biofilms acquire a highly distinctive,
wrinkled appearance. This was also observed when biofilms were
grown in tubes or plates, whereas the control biofilms were
smooth in appearance. Whether the changes in the appearance of
the biofilm are due to morphological changes in the cell or purely
due to differences in the extracellular DNA/lipid content and local-
ization needs to be confirmed via other microscopic techniques.
Carprofen disrupts membrane potential in
M. tuberculosis
To identify the endogenous target of carprofen, attempts were
made to generate spontaneous drug-resistant mutant strains of
M. tuberculosis; however, these were unsuccessful. A similar out-
come was reported by Gold et al.33 while trying to generate strains
resistant to another NSAID, oxyphenbutazone. The inability to
generate spontaneous mutations that confer resistance to carpro-
fen, although inconclusive, suggests that the drug may have pleio-
tropic mechanisms of action or targets a single physiological
process at multiple points. This hypothesis was supported by the
global impact of carprofen on M. tuberculosis gene expression
(Figure 2a and Table S1). Carprofen modified the expression of
675 genes, in contrast to isoniazid, which affects the expression of
<40 genes (Figure 2b).34
The carprofen mRNA signature was contrasted to DMSO-
treated (carrier control) M. tuberculosis alongside other structurally
similar but less anti-TB NSAIDs, ibuprofen and ketoprofen
(Figure 2c and d). Isoniazid was included as a first-line cell wall-
targeting comparator drug. Only 28 genes were significantly
modulated by ketoprofen, an NSAID with no antimycobacterial
property.
The M. tuberculosis response to carprofen did not overlap with
drug signatures generated by first-line anti-TB drugs. None of the
primary drug targets for isoniazid, rifampicin and pyrazinamide
was modulated by carprofen treatment; those for ethambutol
(embAB) were down-regulated. Overall, the distinct response to
drug exposure shows that the mechanisms of action of carprofen
are not the same as first-line anti-TB drugs currently in use, reduc-
ing the likelihood of cross-resistance.
The transcriptional response of M. tuberculosis to carprofen ex-
posure was used to define the class of drug action. The 479 genes
that were significantly induced by carprofen exposure were
enriched with genes involved in the response to microaerophilic/
anaerobic conditions, including enduring hypoxic response35
[hypergeometric probability (HGp) 3.43%10#15], the Wayne model
of non-replicating persistence NRP-236 (HGp 3.73%10#9) and the
low potassium model of persistence37 (HGp 1.75%10#30). The
functional category I.B.7, encompassing miscellaneous oxidore-
ductases and oxygenases, was also enriched (HGp 2.80%10#8), as
were gene ontology (GO) terms for electron transporter activity
GO:0005489/GO:0006118 (HGp 7.92%10#6). The drugs that
resulted in the most similar signature to carprofen were valinomy-
cin (HGp 1.63%10#17), pyrazinamide (HGp 3.82%10#14), pretoma-
nid (HGp 1.38%10#12) and CCCP (HGp 3.31%10#6). A modular
analysis of drug-responsive gene clusters, defined by Boshoff
et al.,38 which significantly overlapped with the carprofen signa-
ture (HGp <0.004, induced GC13/87/121/58/141/101/81/132/60
and repressed GC25/36/95/71/26/70/8/1), mapped to agents
(besides nitric oxide) that inhibit respiration. Valinomycin and CCCP
were also the closest matches to carprofen’s mechanism of action
using this independent unsupervised analysis.
Both valinomycin and CCCP are strong uncouplers that disrupt
membrane potential.39,40 Shared transcriptomic signatures be-
tween these drugs and carprofen likely indicate imbalance in the
respiratory chain or membrane potential that leads to cell death.
Preliminary investigation indicates that carprofen can interfere
with the membrane potential (Figure S2). However, the effect of
carprofen on the membrane potential is much lower than that
of CCCP.
The overlapping transcriptional profiles between pretomanid
and carprofen may be a result of these compounds sharing a simi-
lar mode of action (Figure S3). Pretomanid is known to affect cell-
wall metabolism as well as exert nitric oxide stress41,42 and the
effect of carprofen on these mechanisms need to be investigated.
Novel carprofen analogue displays similar
antimycobacterial effect to carprofen
In a study focused on the synthesis and evaluation of carprofen
analogues, we have identified 2-(6-chloro-9H-carbazol-3-yl)acetic
acid (structure 2 in Figure 3) as a carbazole with similar antimyco-
bacterial properties (MIC99 of 250 mg/L for M. smegmatis mc
2155)
to carprofen [structure 1 in Figure 3]. This analogue lacks the
a-methyl group of the propionic acid moiety at the 2-position of
the carbazole ring in carprofen, which is required for the anti-
inflammatory activity, and instead, 2-(6-chloro-9H-carbazol-3-
yl)acetic acid has an ethanoic acid moiety at the 3-position. These
Repurposing non-steroidal anti-inflammatory drugs JAC
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structural alterations allow for a simple five-step chemical synthe-
sis, utilising a Buchwald–Hartwig amination,43–45 followed by
a modified Ackermark–Kno¨lker cyclization46 as key steps in the
assembly of the carbazole scaffold (Scheme S1 in ‘Synthesis
Supplementary Information’ in the Supplementary data).
The identification of a carprofen analogue with similar antimy-
cobacterial activity and a convenient synthesis route potentiates
the evaluation of a diverse range of analogues. Further studies to
explore the potential of 2-(6-chloro-9H-carbazol-3-yl)acetic acid
and other carprofen analogues are currently ongoing within our
research groups.
Conclusions
Carprofen was developed by Roche47 and is commercially avail-
able as Rimadyl. The requirement for expensive starting materials,
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control. Red colouring indicates induction and blue indicates repression. CRP, carprofen; IBP, ibuprofen; KETO, ketoprofen; INH, isoniazid; CC, carrier
control. The genes identified as significantly differentially expressed in each drug comparison are marked as DEG. (b) Total number of genes that
were significantly up- and down-regulated by drug exposure. (c) Hierarchical clustering of M. tuberculosis responses to drug exposure, showing simi-
larity between replicate treatments (carprofen represented as CAR here). (d) The number of genes significantly modified by each drug exposure in
comparison with carrier control. Overlap of genes induced or repressed by exposure to NSAIDs, showing minimal response to ketoprofen and discrete
isoniazid signature.
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stringent reaction conditions and the lengthy synthetic steps
made the development of other NSAIDs more attractive and
the use of carprofen in humans stopped shortly after its release.
A patent on a simplified process to synthesize carprofen and its
derivatives has been filed in recent years.48 The identification of
the carprofen analogue 2-(6-chloro-9H-carbazol-3-yl)acetic acid,
which shows similar potency to carprofen in preliminary screening,
may help to mitigate issues with the complexity of the chemical
synthesis of carprofen, while retaining the desired antimycobacte-
rial activity.
The anti-inflammatory activity of carprofen has been attributed
to inhibition of phagocytosis by neutrophils.49 This property of
carprofen could have far-reaching implications in the clinical treat-
ment of TB as the primary route of pathogenesis of M. tuberculosis
necessitates the initial, phagocytic uptake of bacteria by host
cells.50
The pleiotropic effects of carprofen on mycobacteria and the
possible likelihood of targeting membrane potential, efflux and
mycobacterial biofilm formation limit the possibility for an emer-
gence of spontaneously resistant mutants and offer alternative
mechanisms of action to the current first-line anti-TB drugs. We
also present a novel carprofen analogue, 2-(6-chloro-9H-carbazol-
3-yl)acetic acid, with similar antimycobacterial activity to carpro-
fen, which may be the first in a series of novel antimycobacterial
carbazoles. Whilst acknowledging that our data relate to a mouse
model, we believe that they warrant further exploration of the syn-
ergistic and immunomodulatory effects of this repurposed drug,
with the ultimate goal of human studies.
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